Physician profile
Barry R Smith
NPI 1871581983
$2,975.36
in general payments reported to CMS, 2019-2025
26 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $77.87 · 2021: $127 · 2022: $387 · 2023: $332 · 2024: $662 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,221.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $656.08 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $351.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.53 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $197.08 | 2020-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $183.37 | 2025 | |
| Novartis Pharmaceuticals Corporation | $177.42 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $160.53 | 2023-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $145.00 | 2019-2025 | Lokelma, Farxiga, Wainua |
| Abiomed | $134.88 | 2022-2025 | Impella |
| Heartflow, INC. | $86.53 | 2024-2025 | |
| Boston Scientific Corporation | $82.70 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $80.10 | 2019-2025 | Dupixent |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.36 | 2019-2025 | Lifevest |
| Bridgebio Pharma, INC. | $66.89 | 2025 | Attruby |
| Novo Nordisk INC | $64.67 | 2023-2024 | Wegovy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $51.17 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $46.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $41.15 | 2022-2023 | Xarelto |
| Azurity Pharmaceuticals, INC. | $34.34 | 2025 | Edarbi |
| Alexion Pharmaceuticals, INC. | $29.37 | 2025 | Ultomiris |
| Akcea Therapeutics, INC. | $27.11 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $20.70 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $19.74 | 2023 | Optimizer |
| Inari Medical, INC. | $16.53 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Alnylam Pharmaceuticals INC. | $13.79 | 2024 | Amvuttra |
| Amarin Pharma, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.